Breast Positron Emission Tomography Technique

1. Eo JS, Chun IK, Paeng JC, Kang KW, Lee SM, Han W, et al. Imaging sensitivity of dedicated positron emission mammography in relation to tumor size. Breast. 2012 Feb. 21(1):66-71. [QxMD MEDLINE Link].

2. Berg WA, Weinberg IN, Narayanan D, Lobrano ME, Ross E, Amodei L, et al. High-resolution fluorodeoxyglucose positron emission tomography with compression ("positron emission mammography") is highly accurate in depicting primary breast cancer. Breast J. 2006 Jul-Aug. 12(4):309-23. [QxMD MEDLINE Link].

3. Paydary K, Seraj SM, Zadeh MZ, Emamzadehfard S, Shamchi SP, Gholami S, et al. The Evolving Role of FDG-PET/CT in the Diagnosis, Staging, and Treatment of Breast Cancer. Mol Imaging Biol. 2018 Mar 7. [QxMD MEDLINE Link].

4. Dai D, Song X, Wang M, Li L, Ma W, Xu W, et al. Comparison of Diagnostic Performance of Three-Dimensional Positron Emission Mammography versus Whole Body Positron Emission Tomography in Breast Cancer. Contrast Media Mol Imaging. 2017. 2017:5438395. [QxMD MEDLINE Link]. [Full Text].

5. Yamamoto Y, Ozawa Y, Kubouchi K, Nakamura S, Nakajima Y, Inoue T. Comparative analysis of imaging sensitivity of positron emission mammography and whole-body PET in relation to tumor size. Clin Nucl Med. 2015 Jan. 40 (1):21-5. [QxMD MEDLINE Link].

6. Shimada H, Setoguchi T, Yokouchi M, Sasaki H, Ishidou Y, Kawamura I, et al. Metastatic bone tumors: Analysis of factors affecting prognosis and efficacy of CT and ¹⁸F-FDG PET-CT in identifying primary lesions. Mol Clin Oncol. 2014 Sep. 2(5):875-881. [QxMD MEDLINE Link]. [Full Text].

7. Pires AO, Borges US, Lopes-Costa PV, Gebrim LH, da Silva BB. Evaluation of bone metastases from breast cancer by bone scintigraphy and positron emission tomography/computed tomography imaging. Eur J Obstet Gynecol Reprod Biol. 2014 Jun 28. [QxMD MEDLINE Link].

8. García Vicente AM, Cruz Mora MA, León Martín AA, Muñoz Sánchez MD, Relea Calatayud F, Van Gómez López O, et al. Glycolytic activity with ¹⁸F-FDG PET/CT predicts final neoadjuvant chemotherapy response in breast cancer. Tumour Biol. 2014 Aug 20. [QxMD MEDLINE Link].

9. Ogino K, Nakajima M, Kakuta M, Hayashi M, Yamaguchi S, Tsuchioka T, et al. Utility of FDG-PET/CT in the Evaluation of the Response of Locally Advanced Breast Cancer to Neoadjuvant Chemotherapy. Int Surg. 2014 Jul-Aug. 99(4):309-18. [QxMD MEDLINE Link]. [Full Text].

10. Marti-Climent JM, Dominguez-Prado I, Garcia-Velloso MJ, Boni V, Peñuelas I, Toledo I, et al. [¹⁸F]fluorothymidine-positron emission tomography in patients with locally advanced breast cancer under bevacizumab treatment: Usefulness of different quantitative methods of tumor proliferation. Rev Esp Med Nucl Imagen Mol. 2014 Jul 22. [QxMD MEDLINE Link].

11. Göktaş İ, Cayvarlı H. The Role of ¹⁸F-FDG PET/CT in Evaluating Elevated Levels of Tumor Markers in Breast Cancer. Mol Imaging Radionucl Ther. 2018 Feb 1. 27 (1):3-9. [QxMD MEDLINE Link]. [Full Text].

12. Balma M, Liberini V, Racca M, et al. Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review. Front Med (Lausanne). 2022. 9:881551. [QxMD MEDLINE Link].

13. Peñuelas I, Domínguez-Prado I, García-Velloso MJ, et al. PET Tracers for Clinical Imaging of Breast Cancer. J Oncol. 2012. 2012:710561. [QxMD MEDLINE Link].

14. Ulaner GA, Goldman DA, Gönen M, et al. Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers. J Nucl Med. 2016 Sep. 57 (9):1350-6. [QxMD MEDLINE Link].

15. Tade FI, Cohen MA, Styblo TM, et al. Anti-3-18F-FACBC (18F-Fluciclovine) PET/CT of Breast Cancer: An Exploratory Study. J Nucl Med. 2016 Sep. 57 (9):1357-63. [QxMD MEDLINE Link].

16. Zhou R, Pantel AR, Li S, et al. [¹⁸F](2S,4R)4-Fluoroglutamine PET Detects Glutamine Pool Size Changes in Triple-Negative Breast Cancer in Response to Glutaminase Inhibition. Cancer Res. 2017 Mar 15. 77 (6):1476-1484. [QxMD MEDLINE Link].

17. Dijkers EC, Oude Munnink TH, Kosterink JG, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010 May. 87 (5):586-92. [QxMD MEDLINE Link].

18. Pabst KM, Decker T, Kersting D, et al. The Future Role of PET Imaging in Metastatic Breast Cancer. Oncol Res Treat. 2022. 45 (1-2):18-25. [QxMD MEDLINE Link].

19. Fiz F, Bottoni G, Treglia G, et al. Diagnostic and Prognostic Role of ¹⁸F-Fluoroestradiol PET in Metastatic Breast Cancer: The Second Youth of an Older Theranostic Concept. J Clin Med. 2022 Jun 22. 11 (13):[QxMD MEDLINE Link].

20. Chae SY, Son HJ, Lee DY, et al. Comparison of diagnostic sensitivity of [¹⁸F]fluoroestradiol and [¹⁸F]fluorodeoxyglucose positron emission tomography/computed tomography for breast cancer recurrence in patients with a history of estrogen receptor-positive primary breast cancer. EJNMMI Res. 2020 May 24. 10 (1):54. [QxMD MEDLINE Link].

21. Hathi DK, Li W, Seo Y, et al. Evaluation of primary breast cancers using dedicated breast PET and whole-body PET. Sci Rep. 2020 Dec 14. 10 (1):21930. [QxMD MEDLINE Link].

22. Satoh Y, Kawamoto M, Kubota K, et al. Clinical practice guidelines for high-resolution breast PET, 2019 edition. Ann Nucl Med. 2021 Mar. 35 (3):406-414. [QxMD MEDLINE Link].

23. Yano F, Itoh M, Hirakawa H, et al. Diagnostic Accuracy of Positron Emission Mammography with ¹⁸F-fluorodeoxyglucose in Breast Cancer Tumor of Less than 20 mm in Size. Asia Ocean J Nucl Med Biol. 2019 Winter. 7 (1):13-21. [QxMD MEDLINE Link].

24. Sueoka S, Sasada S, Masumoto N, et al. Performance of dedicated breast positron emission tomography in the detection of small and low-grade breast cancer. Breast Cancer Res Treat. 2021 May. 187 (1):125-33. [QxMD MEDLINE Link].

25. Sasada S, Kimura Y, Masumoto N, et al. Breast cancer detection by dedicated breast positron emission tomography according to the World Health Organization classification of breast tumors. Eur J Surg Oncol. 2021 Jul. 47 (7):1588-92. [QxMD MEDLINE Link].

26. Sasada S, Masumoto N, Emi A, et al. Malignant prediction of incidental findings using ring-type dedicated breast positron emission tomography. Sci Rep. 2022 Jan 21. 12 (1):1144. [QxMD MEDLINE Link].

27. Muduly DK, Ephraim R, Sultania M, et al. Correlation of 18-fluorodeoxyglucose uptake values on PET-CT scan with histological prognostic markers in breast cancer. Asia Pac J Clin Oncol. 2022 Jul 7. [QxMD MEDLINE Link].

28. Fludeoxyglucose F18 [package insert]. PETNET Solutions, Inc. 2011. Available at [Full Text].

29. Kalinyak JE, Schilling K, Berg WA, Narayanan D, Mayberry JP, Rai R, et al. PET-guided breast biopsy. Breast J. 2011 Mar-Apr. 17(2):143-51. [QxMD MEDLINE Link].

30. Satoh Y, Nambu A, Ichikawa T, Onishi H. Whole-body total lesion glycolysis measured on fluorodeoxyglucose positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer. BMC Cancer. 2014 Jul 21. 14:525. [QxMD MEDLINE Link].

31. Kitajima K, Miyoshi Y, Yamano T, Odawara S, Higuchi T, Yamakado K. Prognostic value of FDG-PET and DWI in breast cancer. Ann Nucl Med. 2018 Jan. 32 (1):44-53. [QxMD MEDLINE Link].

32. Moadel RM. Breast cancer imaging devices. Semin Nucl Med. 2011 May. 41(3):229-41. [QxMD MEDLINE Link].

33. Schilling K, Narayanan D, Kalinyak JE, The J, Velasquez MV, Kahn S, et al. Positron emission mammography in breast cancer presurgical planning: comparisons with magnetic resonance imaging. Eur J Nucl Med Mol Imaging. 2011 Jan. 38(1):23-36. [QxMD MEDLINE Link]. [Full Text].

Thomas F Heston, MD, FAAFP, FASNC, FACNM Director of Nuclear Medicine, Family Care Network Center for Medical Testing; Adjunct Assistant Professor of Radiology, Johns Hopkins University School of Medicine; Visiting Professor, International American University

Thomas F Heston, MD, FAAFP, FASNC, FACNM is a member of the following medical societies: American Academy of Family Physicians, Society of Nuclear Medicine and Molecular Imaging, American Society of Nuclear Cardiology

Disclosure: Nothing to disclose.

Mahan Mathur, MD Assistant Professor of Radiology and Biomedical Imaging, Yale University School of Medicine; Director, Medical Student Education, Associate Director, Diagnostic Radiology Residency Program, Yale-New Haven Hospital

Mahan Mathur, MD is a member of the following medical societies: American College of Radiology, American Roentgen Ray Society, Radiological Society of North America

Disclosure: Nothing to disclose.

Gowthaman Gunabushanam, MD, FRCR Assistant Professor, Department of Diagnostic Radiology, Yale University School of Medicine

Gowthaman Gunabushanam, MD, FRCR is a member of the following medical societies: American Roentgen Ray Society, Connecticut State Medical Society

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article